Solid Biosciences (SLDB) Income from Continuing Operations (2017 - 2024)
Historic Income from Continuing Operations for Solid Biosciences (SLDB) over the last 7 years, with Q4 2024 value amounting to -$38.0 million.
- Solid Biosciences' Income from Continuing Operations fell 8463.55% to -$38.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$120.6 million, marking a year-over-year decrease of 2418.8%. This contributed to the annual value of -$120.6 million for FY2024, which is 2418.8% down from last year.
- According to the latest figures from Q4 2024, Solid Biosciences' Income from Continuing Operations is -$38.0 million, which was down 8463.55% from -$32.9 million recorded in Q3 2024.
- In the past 5 years, Solid Biosciences' Income from Continuing Operations ranged from a high of -$19.0 million in Q2 2020 and a low of -$38.0 million during Q4 2024
- Moreover, its 4-year median value for Income from Continuing Operations was -$24.9 million (2023), whereas its average is -$25.6 million.
- Per our database at Business Quant, Solid Biosciences' Income from Continuing Operations soared by 3761.81% in 2023 and then tumbled by 8463.55% in 2024.
- Quarter analysis of 4 years shows Solid Biosciences' Income from Continuing Operations stood at -$21.4 million in 2020, then plummeted by 54.62% to -$33.0 million in 2022, then soared by 37.62% to -$20.6 million in 2023, then crashed by 84.64% to -$38.0 million in 2024.
- Its last three reported values are -$38.0 million in Q4 2024, -$32.9 million for Q3 2024, and -$25.3 million during Q2 2024.